Press Release
View printer-friendly version << Back
vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimer’s Disease (CTAD)
vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimer’s Disease (CTAD)
-- Azeliragon is the only receptor for advanced glycation endproducts (RAGE) antagonist in clinical development for Alzheimer’s disease --
Details of the poster presentations are as follows:
Title: Effect of mild or moderate hepatic impairment on the
clearance of azeliragon
Poster Number: P30
Category:
Clinical trials: Results
Date:
Location:
Title: Effect of CYP2C8 and CYP3A4 inhibition and CYP induction
on the pharmacokinetics of azeliragon
Poster Number:
P31
Category: Clinical trials: Results
Date:
Location:
Title: Analysis of treatment emergent adverse event incidences in
phase 2 study of azeliragon reveal potential attenuation of psychiatric
system organ class (SOC) adverse events and expected drug effects in
gastrointestinal SOC
Poster Number: P39
Category:
Clinical trials: Results
Date:
Location:
“vTv is committed to pursuing innovative, scientific advancement and to
our goal of developing a safe and impactful treatment for the
Alzheimer’s disease community,” said
About Azeliragon
vTv discovered and developed azeliragon using its proprietary drug discovery platform TTP Translational Technology®. A broad range of human pathologic and experimental biologic investigation suggests that RAGE activation contributes to the pathogenesis of Alzheimer’s disease. Sustained Amyloid-β interactions with RAGE at the blood-brain barrier (BBB) and in neuronal and microglial cells, play potentially major roles in amyloid plaque formation, neuroinflammation and chronic neural dysfunction – all hallmarks of Alzheimer’s disease. Azeliragon, also known as TTP488, is a novel orally active small-molecule antagonist of RAGE.
About STEADFAST
STEADFAST, two identical randomized, double-blind, placebo-controlled
Phase 3 trials, is investigating the efficacy of azeliragon as a
potential treatment to slow the decline in cognition and functional
activities for patients with mild Alzheimer’s disease. The 18-month
trial targeted enrollment of 800 patients (400 each for Part A and B).
Part A enrolled patients in
About
Forward-Looking Statements
This release contains forward-looking statements, which involve risks
and uncertainties. These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
“anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,”
“plan,” “potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and, in each case, their negative or other various or comparable
terminology. All statements other than statements of historical facts
contained in this release, including statements regarding the timing of
our clinical trials, our strategy, future operations, future financial
position, future revenue, projected costs, prospects, plans, objectives
of management and expected market growth are forward-looking statements.
These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Important factors that could cause our results to vary from
expectations include those described under the heading “Risk Factors” in
our Annual Report on Form 10-K and our other filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20171030005152/en/
Source:
Investors:
vTv Therapeutics Inc.
Mike Biega, 617-221-9660
IR@vtvtherapeutics.com
or
Media:
Pure
Communications
Katie Engleman, 910-509-3977
Katie@purecommunications.com